ENPC
LIVE

Serial Number

88278768

Owner

NEUWAY Pharma GmbH

Attorney

LEIGH ANN LINDQUIST

Filing Date

Jan 28, 2019

Add to watchlist:

No watchlists yet
View on USPTO

ENPC Trademark

Serial Number: 88278768 • Registration: 6011047

ENPC is a trademark filed by NEUWAY Pharma GmbH on January 28, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

NEUWAY Pharma GmbH (4 trademarks)

Bonn 53117 , DE

Entity Type: 99

Trademark Details

Filing Date

January 28, 2019

Registration Date

March 17, 2020

Published for Opposition

December 31, 2019

Goods & Services

manufacture of pharmaceutical products, medicinal products, medicaments from pharmaceutical compositions for third parties

Diagnostic preparations for medical and veterinary use; vaccines; pharmaceutical preparations, in particular adjuvants, carriers for active ingredients and drug delivery systems comprising protein based capsids or particles for the release of therapeutic or diagnostic agents consisting of proteins in the form of capsids or particles for medical use in humans or animals, biological implants comprising active ingredients for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation

Chemical, biological, biochemical and biotechnological products and preparations, namely, small molecules, biologics, nucleic acids, proteins, lipids, polysaccharides, enzymes, antibodies, cells, microorganisms, protein-based capsids or particles as well as fragments, fractions and derivatives thereof for laboratory or research use and manufacturing use

Scientific research and development for third parties, namely, in the fields of medicine, pharmacy, diagnostics, chemistry, biology, biochemistry and biotechnology; scientific research and development with regard to the manufacture of pharmaceutical preparations, carriers for active ingredients and drug delivery systems for use in humans or animals, for third parties; development of pharmaceutical preparations, namely, medical products, for the prevention and treatment of neurological, neurodegenerative, psychiatric, immune system related, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, urological, gynecological, reproductive, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, lymphatic, inflammatory, infectious, hematological, renal, genetic, bacterial and viral diseases, sexual dysfunction and pain as well as for gene therapy, vaccination or immunostimmulation for others

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Mar 17, 2025 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 26, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 26, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 26, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 26, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 26, 2022 COAR
REGISTERED-PRINCIPAL REGISTER
Mar 17, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 31, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 31, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 11, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 25, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 5, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 5, 2019 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 31, 2019 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 28, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 28, 2019 GNSL
SUSPENSION LETTER WRITTEN
Oct 28, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 7, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 4, 2019 TROA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 4, 2019 EWAF
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 27, 2019 GNRN
NON-FINAL ACTION E-MAILED
Aug 27, 2019 GNRT
NON-FINAL ACTION WRITTEN
Aug 27, 2019 CNRT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 12, 2019 TCCA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 12, 2019 GNRN
NON-FINAL ACTION E-MAILED
Apr 12, 2019 GNRT
NON-FINAL ACTION WRITTEN
Apr 12, 2019 CNRT
ASSIGNED TO EXAMINER
Apr 9, 2019 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Feb 25, 2019 AMPX
ASSIGNED TO LIE
Feb 21, 2019 ALIE
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 20, 2019 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Feb 14, 2019 PARI
NEW APPLICATION ENTERED
Jan 31, 2019 NWAP